Volume 4.37 | Sep 27

Prostate Cell News 4.37 September 27, 2013
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
 
TOP STORY
RNAi-Mediated Silencing of Myc Transcription Inhibits Stem-Like Cell Maintenance and Tumorigenicity in Prostate Cancer
Researchers investigated the effects of silencing Myc transcription on prostate cancer stem-like cell (CSC) in cell culture and xenograft models of human prostate cancer. Treatment with an effective promoter-targeting siRNA reduced the fraction of CSCs leading to reduced self-renewal, tumor-initiating and metastatic capability. [Cancer Res] Abstract
Derivation of Metabolically Active Hepatocytes from Pluripotent Stem Cells - View On-Demand Webinar Now.
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

The Modulation of Attachment, Growth and Morphology of Cancerous Prostate Cells by Polyelectrolyte Nanofilms
The behavior of cancerous epithelial prostatic cells (PC3) growing on polyelectrolytes coatings was compared to the behavior of immortalized normal prostatic cells (PNT-2). The proliferation rate of PC3 cells was reduced on the poly(allylamine hydrochloride)-terminated surface and slightly increased on the poly(sodium 4-styrenesulphonate) coatings. [Biomaterials] Full Article

Protein Inhibitor of Activated Signal 1-Modulated Smad2/4 Complex Activation Is Involved in Zinc-Induced Cancer Cell Apoptosis
Scientists investigated the therapeutic effect of zinc in prostate cancer chemoprevention for the first time. Exposure to zinc induced apoptosis and resulted in transactivation of p21WAF1/Cip1 in a Smad-dependent and p53-independent manner in prostate cancer cells. [Cell Death Dis] Full Article

Apigenin Inhibits Prostate Cancer Progression in TRAMP Mice via Targeting PI3K/Akt/FoxO Pathway
Researchers showed that apigenin suppressed prostate tumorigenesis in TRAMP mice through the PI3K/Akt/forkhead box O (FoxO) signaling pathway. [Carcinogenesis] Abstract

Deubiquitinating Enzyme Usp12 Is a Novel Co-Activator of the Androgen Receptor
Researchers demonstrated that ubiquitin specific protease 12 (Usp12), in complex with Uaf-1 and WDR20, deubiquitinates the androgen receptor (AR) to enhance receptor stability and transcriptional activity. They showed that Usp12 acts in a pro-proliferative manner by stabilizing AR and enhancing its cellular function. [J Biol Chem] Abstract | Full Article

Metastatic Prostate Cancer Cell-Specific Phage-Like Particles as a Targeted Gene-Delivery System
Phage clone EPTHSWAT (designated by the sequence of inserted peptide) was found to be most selective for PC-3M cells and was observed to internalize PC-3M cells as revealed by immunofluorescence microscopy and electron microscopy. [J Nanobiotechnology] Abstract | Full Article

Early Human Prostate Adenocarcinomas Harbor Androgen-Independent Cancer Cells
Investigators report the propagation of cancer initiating cells directly from Stage I human prostate cancer tissue without selection or genetic manipulation. [PLoS One] Full Article

Influence of Lycopene on Cell Viability, Cell Cycle, and Apoptosis of Human Prostate Cancer and Benign Hyperplastic Cells
Using MTT assay, researchers observed a decrease of cell viability in all cancer cell lines after treatment with lycopene, which decreased the percentage of cells in G0/G1 phase and increased in S and G2/M phases after 96 hours of treatment in metastatic prostate cancer cell lineages. [Nutr Cancer] Abstract

Selenium Biomarkers in Prostate Cancer Cell Lines and Influence of Selenium on Invasive Potential of PC3 Cells
Scientists found that the maximum levels of glutathione peroxidase 1 activity and thioredoxin reductase 1 expression were reached at lower selenium concentrations in LNCaP compared to PC3 cells, and PC3 compared to DU145 cells. [Front Oncol] Abstract

CLINICAL RESEARCH

Genetic Variation in IL-16 miRNA Target Site and Time to Prostate Cancer Diagnosis in African-American Men
Researchers evaluated genetic variants in genes encoding microRNA (miRNA) binding sites for informing of time to prostate cancer diagnosis among ethnically diverse, high-risk men undergoing prostate cancer screening. [Prostate Cancer P D] Abstract

Safety of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients with Concomitant Cardiovascular Risk Factors
Scientists evaluated the safety profile of abiraterone acetate in metastatic castration-resistant prostate cancer men with cardiovascular comorbidity, as little conclusive safety data are available in this patient subset. [Am J Clin Oncol] Abstract

New TeSR™-E8™ is Here For Feeder-Free Culture of Human ES Cells and iPS Cells
 
REVIEWS
Genomic Rearrangements of PTEN in Prostate Cancer
It is clear that PTEN is a powerful biomarker for prostate cancer. Used as a companion diagnostic for emerging therapeutic drugs, fluorescence in situ hybridization analysis of phosphatase and tensin homolog gene (PTEN) is promisingly moving human prostate cancer closer to more effective cancer management and therapies. [Front Oncol] Abstract

Visit our REVIEWS page to see a complete list of reviews in the prostate cell research field.
 
INDUSTRY NEWS
Fred Hutch Receives $11.3 Million NCI Grant Renewal to Lead Pacific Northwest Prostate Cancer Research Consortium
The National Cancer Institute (NCI), a branch of the National Institutes of Health, has awarded an $11.3 million, five-year competitive grant renewal to Fred Hutchinson Cancer Research Center for its continued leadership of a multi-center prostate cancer research consortium, which was first funded in 2002. [Fred Hutchinson Cancer Research Center] Press Release

Exelixis Announces Full Patient Enrollment Target Has Been Achieved for COMET-1
Exelixis, Inc. announced that the enrollment target of 960 patients has been reached for COMET-1, the company’s Phase III pivotal trial of cabozantinib in patients with metastatic castration-resistant prostate cancer. [Exelixis, Inc.] Press Release

Prostate Cancer Foundation Announces New Urine Test for Prostate Cancer Available
A new urine test for prostate cancer that measures minute fragments of RNA is now commercially available to men nationwide through the University of Michigan MLabs. The new test-Mi-Prostate Score-improves the utility of the prostate specific antigen blood test, increases physicians’ ability to pick out high-risk prostate tumors from low-risk tumors in patients, and may help tens of thousands of men avoid unnecessary biopsies. [EurekAlert!] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW TERMIS (Tissue Engineering and Regenerative Medicine International Society) America Conference
November 10-13, 2013
Atlanta, United States

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Research Technician Position – Steroid Receptor Signaling (Baylor College of Medicine)

Postdoctoral Research Associates – Tumor Immune Evasion Mechanism and Inflammation (Hollings Cancer Center)

Postdoctoral Fellow – Prostate Cancer and Head & Neck Cancer (University of Maryland Baltimore)

Research Associate – Prostate Cancer (University of Virginia)

Postdoctoral Position – Prostate Molecular Biology and Cancer Biology (University of California San Francisco)

Postdoctoral Position – Prostate Cancer Biology (University Of Rochester School Of Medicine)

Postdoctoral Position – Cancer Genomics and Epigenomics (Ontario Cancer Institute / Princess Margaret Hospital)

Research Associate II – Anti-Cancer Agents for the Treatment of Prostate Cancer (Johnson & Johnson)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Technologist – Mesenchymal Cell Research (STEMCELL Technologies Inc.)

Research Technologist – Cell Culture Media & Matrices (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Quality Control Analyst – Media (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Learn more about Prostate Cell News: Archives | Events | Contact Us